Karolinska Development AB Stock price

Equities

KDEV

SE0002190926

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 07:59:35 2024-03-28 am EDT 5-day change 1st Jan Change
1.548 SEK +1.57% Intraday chart for Karolinska Development AB +3.06% -8.83%
Sales 2024 * 2M 187K Sales 2025 * 2M 187K Capitalization 418M 39.06M
Net income 2024 * -17M -1.59M Net income 2025 * -16M -1.5M EV / Sales 2024 * 179 x
Net cash position 2024 * 59M 5.52M Net cash position 2025 * 42M 3.93M EV / Sales 2025 * 188 x
P/E ratio 2024 *
-25.8 x
P/E ratio 2025 *
-25.8 x
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 35.96%
More Fundamentals * Assessed data
Dynamic Chart
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round MT
AnaCardio AB announced that it has received SEK 150 million in funding from Industrifonden, Karolinska Development AB, Flerie Invest AB CI
Karolinska Development Takes Part in Portfolio Company Umecrine Cognition's Capital Raise MT
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Umecrine Cognition AB announced that it has received SEK 30.4 million in funding from Karolinska Development AB, Ribbskottet AB, Ab Ility Ab and other investors CI
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan MT
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery CI
Karolinska Development AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Karolinska Unit's Investigational Drug Shows Potential as Anemia Treatment MT
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Karolinska Development's Portfolio Company Biosergen Presents Positive Results from Phase 1 Study of Drug Candidate to Treat Systemic Fungal Infection CI
Karolinska Development AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Karolinska Development AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Karolinska Development AB Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data CI
More news
1 day+1.57%
1 week+3.06%
Current month-1.15%
1 month-3.13%
3 months-8.19%
6 months-1.53%
Current year-8.83%
More quotes
1 week
1.50
Extreme 1.5
1.59
1 month
1.48
Extreme 1.48
1.66
Current year
1.48
Extreme 1.48
1.90
1 year
1.41
Extreme 1.41
1.95
3 years
1.41
Extreme 1.41
11.24
5 years
1.41
Extreme 1.41
11.24
10 years
1.41
Extreme 1.41
26.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 15-12-06
Director of Finance/CFO 56 22-09-30
Chief Tech/Sci/R&D Officer 53 20-05-31
Members of the board TitleAgeSince
Chairman 56 19-12-31
Chief Executive Officer 59 15-12-06
Director/Board Member 55 21-02-18
More insiders
Date Price Change Volume
24-03-28 1.548 +1.57% 45,902
24-03-27 1.524 -0.91% 116,752
24-03-26 1.538 -0.65% 110,176
24-03-25 1.548 -2.52% 159,523
24-03-22 1.588 +5.73% 399,393

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women's health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company's pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Karolinska Development AB - Nasdaq Stockholm